Branford Hills Healthcare Ctr | |
189 Alps Rd, Branford, Connecticut 06405 | |
(203) 481-6221 | |
Name | Branford Hills Healthcare Ctr |
---|---|
Location | 189 Alps Rd, Branford, Connecticut |
Certified By | Medicare and Medicaid |
No. of Certified Beds | 190 |
Occupancy Rate | 67.68% |
Medicare ID (CCN) | 075296 |
Legal Business Name | Csc Enterprises, Inc. |
Ownership Type | For Profit - Individual |
NPI Number | 1366445629 |
Organization Name | CSC ENTERPRISES, INC. |
Doing Business As | BRANFORD HILLS HEALTH CARE CENTER |
Address | 189 Alps Rd, Branford, CT 06405 |
Phone Number | 203-481-6221 |
News Archive
HMP Communications, the authoritative source for education services targeting healthcare professionals for over two decades, announced it has added a new online educational forum at www.CardiovascularLIVE.com. The site offers video instruction and discussion forums for medical professionals.
New research indicates that hospitalized patients with advanced cancer experience many physical and psychological symptoms, and that patients dealing with a higher burden of these symptoms have longer hospital stays and a greater risk for unplanned hospital readmissions.
Cancer Research Technology has signed a deal to provide biotech company ValiRx plc with the global rights to develop a promising compound to treat hormone-resistant prostate cancer.The compound, now called VAL 201, has been shown in pre-clinical tests in mice to stop growth of tumours which have been unresponsive to hormone treatments. VAL 201 blocks genes which can cause prostate cancer to develop. The compound has been shown to be effective in treating mice with breast and prostate cancer and is now rapidly progressing towards the first clinical trials in patients.
Bioengineering researchers at the University of California, San Diego have invented a process to help turn embryonic stem cells into the types of specialized cells being sought as possible treatments for dozens of human diseases and health conditions.
› Verified 6 days ago
NPI Number | 1487396164 |
Organization Name | ABH OPCO LLC |
Address | 189 Alps Rd, Branford, CT 06405 |
Phone Number | 561-451-3277 |
News Archive
HMP Communications, the authoritative source for education services targeting healthcare professionals for over two decades, announced it has added a new online educational forum at www.CardiovascularLIVE.com. The site offers video instruction and discussion forums for medical professionals.
New research indicates that hospitalized patients with advanced cancer experience many physical and psychological symptoms, and that patients dealing with a higher burden of these symptoms have longer hospital stays and a greater risk for unplanned hospital readmissions.
Cancer Research Technology has signed a deal to provide biotech company ValiRx plc with the global rights to develop a promising compound to treat hormone-resistant prostate cancer.The compound, now called VAL 201, has been shown in pre-clinical tests in mice to stop growth of tumours which have been unresponsive to hormone treatments. VAL 201 blocks genes which can cause prostate cancer to develop. The compound has been shown to be effective in treating mice with breast and prostate cancer and is now rapidly progressing towards the first clinical trials in patients.
Bioengineering researchers at the University of California, San Diego have invented a process to help turn embryonic stem cells into the types of specialized cells being sought as possible treatments for dozens of human diseases and health conditions.
› Verified 6 days ago
Ratings from Surveys (Inspections): | |
Ratings from Quality Measures: | |
Ratings from Staffing Data: | |
Overall Rating: |
---|
News Archive
HMP Communications, the authoritative source for education services targeting healthcare professionals for over two decades, announced it has added a new online educational forum at www.CardiovascularLIVE.com. The site offers video instruction and discussion forums for medical professionals.
New research indicates that hospitalized patients with advanced cancer experience many physical and psychological symptoms, and that patients dealing with a higher burden of these symptoms have longer hospital stays and a greater risk for unplanned hospital readmissions.
Cancer Research Technology has signed a deal to provide biotech company ValiRx plc with the global rights to develop a promising compound to treat hormone-resistant prostate cancer.The compound, now called VAL 201, has been shown in pre-clinical tests in mice to stop growth of tumours which have been unresponsive to hormone treatments. VAL 201 blocks genes which can cause prostate cancer to develop. The compound has been shown to be effective in treating mice with breast and prostate cancer and is now rapidly progressing towards the first clinical trials in patients.
Bioengineering researchers at the University of California, San Diego have invented a process to help turn embryonic stem cells into the types of specialized cells being sought as possible treatments for dozens of human diseases and health conditions.
› Verified 6 days ago
Number of Facility Reported Incidents | 0 |
Number of Substantiated Complaints | 0 |
Number of Fines | 1 |
Total Amount of Fines in Dollars | $7345 |
Number of Payment Denials | 0 |
Total Number of Penalties | 1 |
Experience Measure | Provider | National Avg. |
---|---|---|
Percentage of long-stay residents whose need for help with daily activities has increased | 16 | 14.46 |
Percentage of long-stay residents who lose too much weight | 8.75 | 5.51 |
Percentage of low risk long-stay residents who lose control of their bowels or bladder | 67.82 | 48.41 |
Percentage of long-stay residents with a catheter inserted and left in their bladder | 0.19 | 1.79 |
Percentage of long-stay residents with a urinary tract infection | 2.62 | 2.65 |
Percentage of long-stay residents who have depressive symptoms | 1.26 | 5.05 |
Percentage of long-stay residents who were physically restrained | 0 | 0.23 |
Percentage of long-stay residents experiencing one or more falls with major injury | 3.45 | 3.36 |
Percentage of long-stay residents assessed and appropriately given the pneumococcal vaccine | 96.35 | 93.87 |
Percentage of long-stay residents who received an antipsychotic medication | 14.26 | 14.2 |
Percentage of short-stay residents assessed and appropriately given the pneumococcal vaccine | 75.88 | 83.88 |
Percentage of short-stay residents who newly received an antipsychotic medication | 1.95 | 1.79 |
Percentage of long-stay residents whose ability to move independently worsened | 26.42 | 17.09 |
Percentage of long-stay residents who received an antianxiety or hypnotic medication | 17.01 | 19.7 |
Percentage of high risk long-stay residents with pressure ulcers | 7.81 | 7.32 |
Percentage of long-stay residents assessed and appropriately given the seasonal influenza vaccine | 93.28 | 95.98 |
Percentage of short-stay residents who made improvements in function | 63.79 | 67.99 |
Percentage of short-stay residents who were assessed and appropriately given the seasonal influenza vaccine | 89.22 | 82.93 |
News Archive
HMP Communications, the authoritative source for education services targeting healthcare professionals for over two decades, announced it has added a new online educational forum at www.CardiovascularLIVE.com. The site offers video instruction and discussion forums for medical professionals.
New research indicates that hospitalized patients with advanced cancer experience many physical and psychological symptoms, and that patients dealing with a higher burden of these symptoms have longer hospital stays and a greater risk for unplanned hospital readmissions.
Cancer Research Technology has signed a deal to provide biotech company ValiRx plc with the global rights to develop a promising compound to treat hormone-resistant prostate cancer.The compound, now called VAL 201, has been shown in pre-clinical tests in mice to stop growth of tumours which have been unresponsive to hormone treatments. VAL 201 blocks genes which can cause prostate cancer to develop. The compound has been shown to be effective in treating mice with breast and prostate cancer and is now rapidly progressing towards the first clinical trials in patients.
Bioengineering researchers at the University of California, San Diego have invented a process to help turn embryonic stem cells into the types of specialized cells being sought as possible treatments for dozens of human diseases and health conditions.
› Verified 6 days ago
Branford Hills Healthcare Ctr Location: 189 Alps Rd, Branford, Connecticut 06405 Phone: (203) 481-6221 |